QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.106.009894v1 34/11/1909    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burkey, J. L. Articles by Small, D. Search for Related Content PubMed PubMed Citation Articles by Burkey, J. L. Articles by Small, D.

Disposition of [¹⁴C]Ruboxistaurin in Humans

Lilly Research Laboratories, a Division of Eli Lilly and Company, Lilly Corporate Center, and Lilly Laboratory for Clinical Research, Indiana University Hospital and Outpatient Center, Indianapolis, Indiana

Ruboxistaurin is a potent and specific inhibitor of the ß isoforms of protein kinase C (PKC) that is being developed for the treatment of diabetic microvascular complications. The disposition of [¹⁴C]ruboxistaurin was determined in six healthy male subjects who received a single oral dose of 64 mg of [¹⁴C]ruboxistaurin in solution. There were no clinically significant adverse events during the study. Whole blood, urine, and feces were collected at frequent intervals after dosing. Metabolites were profiled by high performance liquid chromatography with radiometric detection. The total mean recovery of the radioactive dose was approximately 87%, with the majority of the radioactivity (82.6 ± 1.1%) recovered in the feces. Urine was a minor pathway of elimination (4.1 ± 0.3%). The major route of ruboxistaurin metabolism was to the N-desmethyl ruboxistaurin metabolite (LY338522), which has been shown to be active and equipotent to ruboxistaurin in the inhibition of PKC_ß. In addition, multiple hydroxylated metabolites were identified by liquid chromatography-mass spectrometry in all matrices. Pharmacokinetics were conducted for both ruboxistaurin and LY338522 (N-desmethyl ruboxistaurin, 1). These moieties together accounted for approximately 52% of the radiocarbon measured in the plasma. The excreted radioactivity was profiled using radiochromatography, and approximately 31% was structurally characterized as ruboxistaurin or N-desmethyl ruboxistaurin. These data demonstrate that ruboxistaurin is metabolized primarily to N-desmethyl ruboxistaurin (1) and multiple other oxidation products, and is excreted primarily in the feces.

This article has been cited by other articles:

				L. Xu, B. Adams, V. V. Jeliazkova-Mecheva, L. Trimble, G. Kwei, and A. Harsch Identification of Novel Metabolites of Colchicine in Rat Bile Facilitated by Enhanced Online Radiometric Detection Drug Metab. Dispos., April 1, 2008; 36(4): 731 - 739. [Abstract] [Full Text] [PDF]